300633 Sonoscape Medical Corp.
- 40.96
- +0.56+1.39%
Sonoscape Medical Corp. News
Medical establishment (300633): The endoscopic field continues to increase, and production lines are being promoted in high-end collaboration
Incident: On April 11, 2024, the company released its 2023 annual report. In 2023, it achieved operating income of 2.120 billion yuan, an increase of 20.29% over the previous year, and net profit of 454 million yuan, an increase of 2 yuan over the previous year
Open Healthcare (300633): Short-term factors put pressure on performance, focus on the release of new mid-range and high-end products
Incident: The company released its report for the first quarter of 2024. In the first quarter of 2024, it achieved operating income of 479 million yuan (+1.33%), net profit to mother of 100 million yuan (-27.65%), deducting zero non-net profit.
Established Healthcare (300633.SZ): A total cost of 91.829,500 yuan to repurchase 2,077,400 shares
Gelonghui Medical (300633.SZ) announced on April 30, 2024, that as of April 30, 2024, the company had repurchased 2,077,400 shares of the company's shares through centralized bidding transactions, accounting for 0.48% of the company's current total share capital. The highest transaction price was 49.37 yuan/share, the lowest transaction price was 32.31 yuan/share, and the transaction amount was 91.8295 million yuan (excluding transaction fees).
Nomura Adjusts Sonoscape Medical's Price Target to 49.97 Yuan From 55.47 Yuan, Keeps at Buy
03:34 AM EDT, 04/29/2024 (MT Newswires) -- Nomura Adjusts Sonoscape Medical's Price Target to 49.97 Yuan From 55.47 Yuan, Keeps at Buy Price (RMB): ¥41.46, Change: ¥+0.27, Percent Change: +0.66%
Kaili Healthcare (300633) 2024 Quarterly Report Review: Affected by the high base, 24Q1 performance growth rate is under pressure
Matters: The company released its quarterly report for 2014, with operating income of 479 million yuan (+1.33%), net profit of 100 million yuan (-27.65%) to mother, deducting non-net profit of 92 million yuan (-26.55%). Review
Open Healthcare (300633): Under pressure from a high base, the growth rate is expected to improve quarterly throughout the year
Guide to this report: 2024Q1's performance is in line with expectations. The growth rate is under pressure under pressure under pressure. As the base decreases quarterly, equipment renewal support, and bidding gradually ease, the company's performance is expected to improve quarter by quarter. Key investment points: Maintain an increase in holdings rating. 2 024
Kaili Healthcare (300633) 2024 Q1 performance review: Under pressure from a high base, the growth rate is expected to improve quarterly throughout the year
Guide to this report: 2024Q1's performance is in line with expectations. The growth rate is under pressure at a high base. As the base decreases quarterly, equipment renewal support, and tendering gradually eases, the company's performance is expected to improve quarter by quarter. Key investment points: Maintain an increase in holdings rating. 2024Q
Kaili Healthcare (300633.SZ) announced first-quarter results, net profit of 100 million yuan, a decrease of 27.65%
Kaili Healthcare (300633.SZ) released its report for the first quarter of 2024. The company's revenue was 479 million yuan, an increase of 1.33% over the previous year. Net profit attributable to shareholders of listed companies was 100 million yuan, a year-on-year decrease of 27.65%. Net profit attributable to shareholders of listed companies after deducting non-recurring profit and loss was 92.22,900 yuan, a year-on-year decrease of 26.55%. Basic earnings per share were $0.2326.
Established Healthcare (300633): 1Q24 revenue grew steadily under a high base
Under the high base, the revenue of 1Q24 companies maintained an upward trend, maintaining that the “buy” rating company 1Q24 achieved revenue of 479 million yuan (yoy +1.3%), and net profit of 100 million yuan (yoy -27.7%)
Express News | Open Medical Talk “EU Launches Medical Device Procurement Market Entry Survey to China”: Waiting for Development
Establishing Healthcare (300633): Multi-line integration, fusion take-off, management quality and efficiency to a new level
The company's 2023 revenue was 2.120 billion yuan (up 20.29% year on year), net profit to mother was 454 million yuan (up 22.28% year on year), and 2023 Q4 revenue was 652 million yuan (up 2 percent year over year)
Open Healthcare (300633): Steady growth in performance, looking forward to the release of new products
Core view The company's annual report results are in line with expectations. Short-term results may be under pressure in the first quarter due to the influence of high base figures and industry policies on bidding. The growth rate is expected to increase in the second half of the year, and the equipment renewal policy is expected to make an incremental contribution to the industry. The company is on ultrasound
Open Source Securities released a research report on April 18 stating that it gave Kaishi Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) R&D innovation enriches the product pipeline, and two-wheel drive in the soft m
Open Source Securities released a research report on April 18 stating that it gave Kaishi Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) R&D innovation enriches the product pipeline, and two-wheel drive in the soft mirror+ultrasound business unlocks greater performance potential; 2) the revenue scale effect has been formed, and the net profit growth rate is expected to exceed the revenue growth rate. (Mainichi Keizai Shimbun)
Kaili Medical opened Huizhen Surgery Innovation Experience Center in Baoshan High-tech Zone in Shanghai
On April 15, the Huizhen Surgery Innovation Experience Center was officially opened in Baoshan High-tech Zone in Shanghai. The Innovation Experience Center showcased cutting-edge medical innovations in the field of minimally invasive surgery. As an innovative experience base for integrated diagnosis and treatment solutions such as Huizhen Hyperabdominal Joint, Multi-mirror Joint, and Zhihui Operating Room, the future will rely on Baoshan District's policy support, take advantage of Shanghai's advantages in international medical device exchanges, focus on the popularization of the integrated concept and technology of minimally invasive diagnosis and treatment, and create a new model of “industry-research medical education” matrix development and international development.
Dongfang Wealth Securities released a research report on April 16 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the ultrasound business is growing steadily, and the endoscopy business mai
Dongfang Wealth Securities released a research report on April 16 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the ultrasound business is growing steadily, and the endoscopy business maintains a high growth rate; 2) strengthening R&D investment in high-end products to enhance product strength; 3) speeding up the overseas localization layout, and overseas revenue growth is impressive; 4) the cost level is relatively stable, and profitability is rising steadily. (Mainichi Keizai Shimbun)
Donghai Securities released a research report on April 15 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the overall performance is in line with expectations; 2) the development of ultraso
Donghai Securities released a research report on April 15 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the overall performance is in line with expectations; 2) the development of ultrasound is steady, and the prospects for new endovascular ultrasound products are promising; 3) soft lenses are growing rapidly, and minimally invasive surgery continues to expand; 4) gross margin has increased significantly and profitability has increased. (Mainichi Keizai Shimbun)
Guohai Securities released a research report on April 14 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the color ultrasound sector is growing steadily and continues to introduce new produ
Guohai Securities released a research report on April 14 stating that it gave Kaisei Healthcare (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the color ultrasound sector is growing steadily and continues to introduce new products; 2) the soft mirror sector maintains rapid growth, and its leading position in the country is stable. (Mainichi Keizai Shimbun)
Open Healthcare (300633): Strong growth in robust ultrasound endoscopy
Key investment results were generally in line with expectations. In 2023, the company achieved operating income of 2.120 billion yuan (+20.29%), net profit attributable to mother of 454 million yuan (+22.88%), and net profit of 442 million yuan after deducting non-return to mother (+
Huaan Securities released a research report on April 14 stating that it gave Kaishi Medical (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the endoscopy sector still achieved rapid growth throughout the year, with a year-on-yea
Huaan Securities released a research report on April 14 stating that it gave Kaishi Medical (300633.SZ) a purchase rating. The main reasons for the rating include: 1) the endoscopy sector still achieved rapid growth throughout the year, with a year-on-year increase of about 39%; 2) the company is actively expanding the minimally invasive surgery sector and is expected to maintain rapid growth in the future. (Mainichi Keizai Shimbun)
SDIC Securities released a research report on April 14 stating that it will maintain its health (300633.SZ) purchase rating. The main reasons for the rating include: 1) the company released its 2023 annual report, with stable and rapid performance growth;
SDIC Securities released a research report on April 14 stating that it will maintain its health (300633.SZ) purchase rating. The main reasons for the rating include: 1) the company released its 2023 annual report, with stable and rapid performance growth; 2) ultrasound: high revenue share, stable growth, high-end product trend and full scenario; 3) endoscopy: the core driving force of the company's performance growth, which is expected to maintain a rapid growth trend; 4) overseas business: continuous improvement of layout, localization, academic interaction, and product promotion. (Mainichi Keizai Shimbun)
Analysis
Price Target
No Data
